>…interestingly no less an authority than josh berger himself posted a slide including polymerase inhibitors with telaprivir as the future of HCV therapy<
The JPM webcast was the first time I heard Boger mention the polymerase-inhibitor class explicitly. Boger chooses his words carefully, so maybe this is significant.
Market Data 
Markets 
AI
